{"id":"W2149731696","doi":"10.1016/s1474-4422(10)70254-4","title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","year":2010,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":680,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"UCB Pharma; U.S. Food and Drug Administration; Schering-Plough; National Institutes of Health; H. Lundbeck A/S; Teva Pharmaceutical Industries; Pfizer; Michael J. Fox Foundation for Parkinson's Research","keywords":"Neurturin; Medicine; Clinical endpoint; Consolidated Standards of Reporting Trials; Adverse effect; Randomized controlled trial; Clinical trial; Internal medicine; Surgery; Neurotrophic factors; Glial cell line-derived neurotrophic factor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009691371,0.0001998928,0.0005541702,0.00005593176,0.0001048445,0.00001675029,0.0006799223,0.0001898661,0.00004823666],"category_scores_gemma":[0.0002372087,0.0001385703,0.000313995,0.00007137697,0.0002792426,0.000003050372,0.000128157,0.0003169799,0.000007003432],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000002189131,"about_ca_system_score_gemma":0.0001782017,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00000759605,"about_ca_topic_score_gemma":0.0001491717,"domain_scores_codex":[0.9982587,0.0003467307,0.0003313358,0.0004168984,0.0001738985,0.0004724287],"domain_scores_gemma":[0.9983759,0.0002887153,0.0001822294,0.000897512,0.0001379105,0.0001177264],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6318261,0.00008836322,0.00008340308,0.000008644529,0.00009853802,0.00000392744,0.000006414906,0.00005205378,0.3664601,0.00003790405,0.0009383603,0.0003961635],"study_design_scores_gemma":[0.8111575,0.003875475,0.000135123,9.302787e-7,0.00007147087,0.000009576416,0.000001120831,0.0001566164,0.1525927,0.0002106186,0.0316522,0.0001366659],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911222,0.0006207719,0.00005522883,0.003394905,0.0006464647,0.003931122,0.00006184509,0.00001756782,0.0001498784],"genre_scores_gemma":[0.993763,0.0003448213,0.00006178251,0.001865876,0.002203094,0.001417111,0.00007149988,0.00004043277,0.0002323262],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2138674,"threshold_uncertainty_score":0.5650731,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03476311458167437,"score_gpt":0.3135376124543153,"score_spread":0.2787744978726409,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}